The immune escape in melanoma: Role of the impaired dendritic cell function

Expert Review of Clinical Immunology

Volumn 10, Issue 10, 2014, Pages 1395-1404

  Tucci, Marco ^a   Stucci, Stefania ^a   Passarelli, Anna ^a   Giudice, Giuseppe ^a   Dammacco, Franco ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

dendritic cells; melanoma; microenvironment; STAT; Treg cells

Indexed keywords

B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; INTERLEUKIN 10; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; SIPULEUCEL T; STAT PROTEIN;

ACCESSORY CELL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL INFILTRATION; CELL MATURATION; CROSS PRESENTATION; CYTOTOXICITY; DENDRITIC CELL; ENZYME ACTIVATION; HUMAN; IMMUNE SYSTEM; MELANOMA; MELANOMA CELL; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; TUMOR ESCAPE;

ANIMALS; DENDRITIC CELLS; HUMANS; MELANOMA; TUMOR ESCAPE;

EID: 84907277029     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.955851     Document Type: Review

References (84)

1. Caini S, Gandini S, Sera F, et al. Meta-Analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer 2009;45:3054-63
2. Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006;203:1859-65
3. Della Bella S, Nicola S, Brambilla L, et al. Quantitative and functional defects of dendritic cells in classic kaposi's sarcoma. Clin Immunol 2006;119:317-29
4. Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-Associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75:517-24
5. Andersen MH, Gehl J, Reker S, et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003;13:449-59
6. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8
7. Urosevic M, Braun B, Willers J, et al. Expression of melanoma-Associated antigens in melanoma cell cultures. Exp Dermatol 2005;14:491-7
8. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Ann Rev Immunol 2006;24:175-208
9. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev 2010;234:45-54
10. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52
11. Shurin MR, Shurin GV, Lokshin A, et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: Friends or enemies? Cancer Metastasis Rev 2006;25:333-56
12. Jacobs JFM, Nierkens S, Figdor CG, et al. Regulatory T cells in melanoma: The final hurdle towards effective immunotherapy? Lancet Oncol 2012;13:e32-42
13. McCarter MD, Baumgartner J, Escobar GA, et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 2007;10:2854-60
14. Polak ME, Borthwick NJ, Gabriel FG, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007;96:1879-87
15. +Treg. Eur J Immunol 2009;39: 1323-33
16. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107:4275-80
17. Alexandrescu DT, Ichim TE, Riordan NH, et al. Immunotherapy for melanoma: Current status and perspectives. J Immunother 2010;33:570-90
18. Umansky V. New strategies for melanoma immunotherapy. How to overcome immunosuppression in the tumor microenvironment. Oncoimmunology 2012;5:765-7
19. Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009;58:1-14
20. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003;170:1257-66
21. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
22. Tucci M, Stucci S, Strippoli S, et al. Dendritic cells and malignant plasma cells: An alliance in multiple myeloma tumor progression? Oncologist 2011;11:1040-8
23. Dhodapkar M, Dhodapkar K, Palucka AK. Interactions of tumor cells with dendritic cells: Balancing immunity and tolerance. Cell Death Differ 2008;15:39-50
24. Fujimura T, Kambayashi Y, Aiba S. Crosstalk between regulatory T-cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 2012;1:1433-4
25. Mellman I. Dendritic cells: Master regulators of the immune response. Cancer Immunol Res 2013;1:145
26. Nouri-Shirazi M, Bancherau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000;165:3797-803
27. Collin M, Mcgover N, Haniffa M. Human dendritic cell subsets. Immunology 2013;140:22-30
28. Tucci M, Quatraro C, Lombardi L, et al. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: Role of interleukin-18. Arthritis Rheum 2008;58: 251-62
29. Spel L, Boelens JJ, Nierkens S, Boes M. Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology 2013;2:e26403
30. Palucka K, Banchereau J, Mellman I. Designing vaccines based onbiology of human dendritic cell subsets. Immunity 2010;33:464-78
31. Mellman I, Steinman RM. Dendritic cells: Specialised and regulated antigen processing machines. Cell 2001;106:255-8
32. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001;106:263-6
33. Failli A, Legitimo A, Orsini G, et al. Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma. Cancer Lett 2013;337: 184-92
34. Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003;200: 255-68
35. Gerner MY, Mescher MF. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol 2009;182:2726-37
36. Ataera H, Hyde E, Price KM, et al. Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One 2011;6:e17515
37. Charles J, Di Domizio J, Salameire D, et al. Characterization of circulating dendritic cells in melanoma: Role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol 2010;130: 1646-56
38. Ito M, Minamiya Y, Kawai H, et al. Tumor-derived TGFb-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 2006;176:5637-43
39. Ladanyi A, Kiss J, Somlai B, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007;56: 1459-69
40. Klarquist JS, Janssen EM. Melanoma-infiltrating dendritic cells. Limitations and opportunities of mouse models. Oncoimmunology 2012;9:1584-93
41. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74
42. Fujimura T, Mahnke K, Enk AH. Myeloid derived suppressor cells and their role in tolerance induction in cancer. J Dermatol Sci 2010;59:1-6
43. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007;13:5243-8
44. Tanikawa T, Wilke CM, Kryczek I, et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 2012;72:420-9
45. Fujimura T, Kambayashi Y, Aiba S. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 2012;1:1433-4
46. Jordan KR, Amaria RN, Ramirez O, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunopathol 2013;62:1711-22
47. Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol 2011;2011:430394
48. Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer. Adv Cancer Res 2010;107:57-117
49. +Regulatory T Cells. J Surg Res 2007;141:72-7
50. Apostolou I, Verginis P, Kretschmer K, et al. Peripherally induced Treg: Mode, stability and role in specific tolerance. J Clin Immunol 2008;28:619-24
51. Attia P, maker AV, Haworth LR, et al. Inability of a fusion protein of IL-2 and diphtheria toxin to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28:582-92
52. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51
53. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8: 945-54
54. Hodgea DR, Hurtb EM, Farrar WL, The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005;41:2502-12
55. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002;2:410-16
56. Kortylewski M, Jove E, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005;24: 315-27
57. Borin Scutti JA, Matsuo AL, Valenca Pereira F, et al. Role of SOCS-1 gene on melanoma cell growth and tumor development. Transl Oncol 2011;4: 101-9
58. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21:7001-10
59. Pansky A, Hildebrand P, Fasler-Kan E, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-Alpha. Int J Cancer 2000;85: 720-5
60. Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997;272:79-85
61. Li Z, Metze D, Nashan D, et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 2004;123:737-45
62. Lee I, Fox PS, Ferguson SD, et al. The expression of p-STAT3 in stage IV melanoma: Risk of CNS metastasis and survival. Oncotarget 2012;3:336-44
63. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999;59:5059-63
64. Homsi J, Cubitt CL, Zhang S, et al. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res 2009;19:167-75
65. Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: Releasing the restraints on anti-Tumor immunity for patients with melanoma. Cancer J 2012;18: 153-9
66. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;22: 237-51
67. Holmgaard RB, Zamarin D, Munn DH, et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013;210:1389-402
68. Shirota H, Klinman DM. Use of CpG oligonucleotides for cancer immunotherapy and their effect on immunity in the tumor microenvironment. Immunotherapy 2013;5: 787-9
69. Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002;196: 541-9
70. Palucka K, Bancherau J. Dendritic cell-based therapeutic cancer vaccines. Immunity 2013;39:38-48
71. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase-III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70
72. Agrawai S, Reemtsma K, Bagiella E, et al. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenity of mouse melanoma. Cell Immunol 2004;228: 130-7
73. Benencia F, Sprague L, McGinty J, et al. Dendritic cells, the tumor microenvironment an the challenges for an effective antitumor vaccination. J Biomed Biotechnol 2012;2012:425476
74. Kantoff PW, Higano CS, Shore MD, et al. Sipuleucel-T immunotheraphy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
75. Tel J, Aarntzen EHJG, Baba T, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013;73: 1063-75
76. Fidgor CL, de Vries IJM, Lesterhuis WJ, Melief CJM. Dendritic cell immunotheraphy: Mapping the way. Nat Med 2004;10:475-80
77. Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004;5:1134-42
78. Laurent S, Carrega P, Saverino D, et al. CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 2010;71:934-41
79. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: An overview of preclinical and translational research. Cancer Immunol 2013;13:5
80. Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013;1:32-42
81. Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-710
82. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;30: 2507-16
83. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/ kg: Real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014;12:116
84. Merelli B, Massi D, Cattaneo L, Mandalà M. Targeting the PD1/PDL1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014;89:140-65